Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer Alice Y. HoShervin TabriziHeather L. McArthur Review 29 October 2021 Pages: 229 - 241
Emerging immunotherapeutic strategies for the treatment of breast cancer Laura A. HuppertVeronica MariottiHatem H. Soliman Review 30 October 2021 Pages: 243 - 255
Breast cancer immune microenvironment: from pre-clinical models to clinical therapies Brooke E. WilsonChiara GorriniDavid W. Cescon Review 03 November 2021 Pages: 257 - 267
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis Francesca PoggioLucia Del MastroMarco Tagliamento Review 03 November 2021 Pages: 269 - 275
Classes of therapeutics to amplify the immune response Yang HuMark E. Burkard Review 17 November 2021 Pages: 277 - 289
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies Evanthia T. Roussos TorresLeisha A. Emens Review 30 October 2021 Pages: 291 - 302
Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics Gail Lewis PhillipsJun GuoBen-Quan Shen Preclinical study Open access 27 October 2021 Pages: 303 - 317
Upregulation of estrogen receptor alpha (ERα) expression in transgenic mice expressing human CYP4Z1 Christopher Khayeka-WandabwaJie ZhaoMatthias Bureik Preclinical study 01 November 2021 Pages: 319 - 326
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict) Paul JankJudith Lea LindnerWolfgang Daniel Schmitt Preclinical study Open access 16 November 2021 Pages: 327 - 333
qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer Ke ZuoXiaoying YuanWentao Yang Preclinical study 19 November 2021 Pages: 335 - 344
Oncologic outcomes of immediate breast reconstruction in young women with breast cancer receiving neoadjuvant chemotherapy Zhen-Yu WuHee Jeong KimBeomSeok Ko Clinical trial 31 October 2021 Pages: 345 - 354
Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study Marco KlingerAgnese LosurdoArmando Santoro Clinical trial 09 November 2021 Pages: 355 - 363
Breast cancer outcomes following immediate breast reconstruction with implants versus autologous flaps: a propensity score-matched study Zhen-Yu WuJing HanBeomSeok Ko Clinical trial 10 November 2021 Pages: 365 - 373
Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade? Luderve RosierYu WangKaren Daily Clinical trial 17 November 2021 Pages: 375 - 383
Dietary supplement use and documentation in a breast cancer survivorship clinic Julia SilverAlyson GoldenbergAnne Moore Clinical trial 24 November 2021 Pages: 385 - 388
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study Anna R. SchreiberJodi KagiharaJennifer R. Diamond Epidemiology Open access 27 October 2021 Pages: 389 - 399
The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer J. Asher JenkinsSchelomo MarmorTodd M. Tuttle Epidemiology 29 October 2021 Pages: 401 - 407
Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer K. A. NyropE. M. DamoneH. B. Muss Epidemiology 05 November 2021 Pages: 409 - 422
Supervised machine learning model to predict oncotype DX risk category in patients over age 50 Kate R. PawloskiMithat GonenMahmoud El-Tamer Epidemiology 09 November 2021 Pages: 423 - 430
A catalog of curated breast cancer genes Muthiah BoseJan BenadaMaria Rossing Epidemiology Open access 10 November 2021 Pages: 431 - 441
Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis Tiia J. HonkanenMilla E. K. LuukkainenJussi P. Koivunen Epidemiology Open access 24 November 2021 Pages: 443 - 450
Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer Harriet T. RothschildMary Kathryn AbelRita A. Mukhtar Epidemiology Open access 24 November 2021 Pages: 451 - 458
Impact of taxane-based chemotherapy among older women with breast cancer on cognition and quality of life: a longitudinal pooled analysis Brent J. SmallMarie LangeFor the Thinking Living with Cancer C. O. G.-Age Studies Epidemiology 24 November 2021 Pages: 459 - 469
Exclusion criteria of breast cancer clinical trial protocols: a descriptive analysis Clara WanNicole E. CastonGabrielle B. Rocque Brief Communication 31 October 2021 Pages: 471 - 475
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study Sandro BarniFrancesco CognettiFausto Petrelli Brief Communication 24 November 2021 Pages: 477 - 480
